For example, many of the CML patients develop overt resistance to imatinib due to mutations in BCR-ABL, and T315I mutation appears to be resistant to Imatinib and the next generation drugs nilotinib and dasatinib [7, 8, 14]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.